4 news items
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
TOVX
23 May 24
by facilitating the development and expediting the review of therapies with potential to treat serious conditions and fill an unmet medical need. Benefits
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers
TOVX
17 Apr 24
new areas that may benefit from VCN-01. Late last year it signed
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
TOVX
8 Apr 24
results and benefits; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
TOVX
25 Mar 24
; the ability to complete clinical trials on time and achieve the desired results and benefits,; the ability to obtain regulatory approval
- Prev
- 1
- Next